Quantcast
Last updated on April 23, 2014 at 11:40 EDT

Health News Archive - May 27, 2010

PARIS, May 27, 2010 /PRNewswire/ -- - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its Clinical Safety* and Efficacy Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced the launch of the ExoSeal(TM) Vascular Closure Device.

WALTHAM, Mass., May 27 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read).

MANCHESTER, England, May 27 /PRNewswire/ -- After women have been confined to flats through the months of cold weather, they're more eager than ever to toss their flats in the closet and don fashionable heels, regardless of the pain and discomfort they cause.

BEIJING, May 27 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2010(1). First Quarter Fiscal 2010 Highlights -- Total net revenues in the first quarter of 2010 were RMB76.2 million ($11.2 million), a 36.6% increase from the corresponding period in 2009. -- Gross profit in the first quarter of 2010 was RMB49.1 million ($7.2 million), a 30.4% increase from the corresponding period in 2009. -- Non-GAAP Net income(2) in the first quarter of 2010 was RMB24.2 million ($3.5 million), a 10.7% increase from the corresponding period in 2009. -- Both Non-GAAP basic and diluted earnings per American Depository Share ("ADS")(3) for the first quarter of 2010 were RMB0.49 ($0.07). -- Adjusted EBI

NEW YORK, May 27 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC).

d6b8d31580f472f04e968f89e2dc1d811

A US government investigation has found that makers and sellers of ginseng, echinacea and other herbal supplements often make false claims that the products can cure cancer or replace prescription medications.

9ade6979a6dbfad7685e802e3eb626c71

US researchers said Wednesday that heavy smokers who get lung cancer may have tens of thousands of genetic mutations.

EMERYVILLE, Calif., May 27 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of Dr. Richard I. Weiner, Ph.D., to the company's Scientific Advisory Board. Dr.

BURLINGTON, Mass., May 27 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased coronary tissue and guide therapeutic interventions, today announced that its next-generation LipiScan(TM) IVUS Coronary Imaging System will be featured at EuroPCR 2010, an international educational conference focused on introducing the latest techniques, updates and breakthrough science to the interventional cardiology community.